FASTER Act of 2021
Summary
The FASTER Act of 2021 (S.578) was signed into law on April 23, 2021, expanding food allergen labeling requirements to include sesame. This is a completed legislative action with no ongoing market impact for retail investors.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The FASTER Act of 2021 is already signed into law, with no ongoing legislative process.
- 2.The bill's primary effect was on food labeling requirements for sesame, a compliance cost already incurred by manufacturers.
- 3.No current market-moving implications for retail investors from this completed action.
Market Implications
No current market implications. The FASTER Act of 2021 was signed into law over five years ago, and its labeling requirements are already in effect. No publicly traded companies are materially affected by this completed legislation.
Full Analysis
The FASTER Act of 2021, sponsored by Sen. Tim Scott (R-SC), was signed into law on April 23, 2021, as Public Law No. 117-11. The bill amends the Federal Food, Drug, and Cosmetic Act to expand the definition of major food allergen to include sesame, requiring food manufacturers to label sesame as an allergen on packaged foods. The bill also mandates a report from the Department of Health and Human Services on food allergy research and data collection. As a signed law from the 117th Congress (2021-2023), this is a historical event with no current legislative momentum or market implications. The bill does not authorize or appropriate any specific funding amount. The primary impact was on food manufacturers who needed to update labeling to include sesame, but this compliance cost is already absorbed. No specific publicly traded companies are directly affected in a way that would create a current investment signal. The bill's bipartisan cosponsorship (8 senators, evenly split between parties) and unanimous passage in the Senate indicate broad support, but the market impact is negligible for retail investors today.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend the Federal Food, Drug, and Cosmetic Act to include barley, rye, and oats as major food allergens, and for other purposes.
To amend the Federal Food, Drug, and Cosmetic Act to include gluten-containing grain in the definition of a major food allergen.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
FURTHER MODIFYING THE SCOPE OF PRODUCTS OF CANADA SUBJECT TO THE ADDITIONAL DUTIES IMPOSED TO OFFSET CANADIAN DISCRIMINATION AGAINST THE COMMERCE OF THE UNITED STATES WITH RESPECT TO MOTOR VEHICLES
This proclamation modifies the list of Canadian products subject to a 50% additional ad valorem duty imposed under Section 338 of the Tariff Act of 1930, removing some products from the duty and adding others, effective October 30, 2026. The action is part of an ongoing dispute over Canada's motor vehicle tariff scheme and is intended to offset discrimination against U.S. commerce. The President directs implementation through the Harmonized Tariff Schedule and authorizes U.S. Customs and Border Protection to issue rules.
DECREASING HOUSING COSTS FOR THE AMERICAN PEOPLE
This executive order directs the Federal Housing Finance Agency to create pilot programs for automatic cancellation of mortgage insurance when borrowers have sufficient equity, and to expand a title insurance pilot to reduce costs for refinancing. It establishes a task force to promote manufactured housing by standardizing permits and reducing regulatory barriers. It also orders the Departments of Agriculture and Veterans Affairs to reduce interest rates on direct home loans.
Advancing Women's Health to Improve Outcomes in All Phases of Life
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →